[{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ATP citrate lyase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ATP citrate lyase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Bempedoic Acid","moa":"ATP synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0.51000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.51000000000000001,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Esperion Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Serometrix","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Esperion Therapeutics \/ ESPERION","highestDevelopmentStatusID":"4","companyTruncated":"Esperion Therapeutics \/ ESPERION"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":1.1299999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.1299999999999999,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"Esperion Therapeutics \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"H.C. Wainwright & Co. ","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ H.C. Wainwright & Co. ","highestDevelopmentStatusID":"12","companyTruncated":"Esperion Therapeutics \/ H.C. Wainwright & Co. "},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Bempedoic Acid","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":1.26,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.26,"dosageForm":"Tablet, Film Coated","sponsorNew":"Esperion Therapeutics \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"Esperion Therapeutics \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Esperion Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Nexletol(bempedoic acid) is an adenosine triphosphate-citrate lyase inhibitor indicated as an adjunct to diet and statin therapy for heart attack, hypercholesterolaemia & cardiovascular diseases.

                          Brand Name : Nexletol

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 22, 2024

                          Lead Product(s) : Bempedoic Acid

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The collaboration combines Esperion Therapeutics’ NILEMDO (bempedoic acid), an ACL inhibitor, with Daiichi Sankyo’s commercial capabilities for cardiovascular medicines.

                          Brand Name : Nilemdo

                          Molecule Type : Small molecule

                          Upfront Cash : $30.0 million

                          January 03, 2024

                          Lead Product(s) : Bempedoic Acid

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Daiichi Sankyo

                          Deal Size : $1,255.0 million

                          Deal Type : Collaboration

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Nexletol (bempedoic acid) is indicated as an adjunct to diet and maximally tolerated statin therapy for treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lower...

                          Brand Name : Nexletol

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 19, 2022

                          Lead Product(s) : Bempedoic Acid

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : NEXLETOL (bempedoic acid) is indicated as an adjunct to diet and maximally tolerated statin therapy for treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lower...

                          Brand Name : Nexletol

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 07, 2022

                          Lead Product(s) : Bempedoic Acid

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Esperion intends to use the net proceeds from the offering to fund the ongoing commercialization efforts for NEXLETOL and NEXLIZET, research and clinical development of current or additional pipeline candidates, and general corporate purposes.

                          Brand Name : Nexletol

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 02, 2021

                          Lead Product(s) : Bempedoic Acid

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved

                          Sponsor : H.C. Wainwright & Co.

                          Deal Size : $225.0 million

                          Deal Type : Public Offering

                          blank

                          06

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Bempedoic acid is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of ...

                          Brand Name : Nexlizet

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 01, 2021

                          Lead Product(s) : Bempedoic Acid,Ezetimibe

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The agreement combines Esperion Therapeutics’ first-in-class ATP Citrate Lyase (ACL) inhibitor, bempedoic acid, with Daiichi Sankyo’s commercial capabilities, as well as synergies with their existing portfolio of cardiovascular medicines.

                          Brand Name : Nexlizet

                          Molecule Type : Small molecule

                          Upfront Cash : $30.0 million

                          April 26, 2021

                          Lead Product(s) : Bempedoic Acid,Ezetimibe

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Daiichi Sankyo

                          Deal Size : $1,130.0 million

                          Deal Type : Partnership

                          blank

                          08

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The aim of this Phase 2 study was to evaluate LDL-C lowering when NEXLETOL was initiated together with ezetimibe (10 mg) and atorvastatin (20 mg), as compared with placebo.

                          Brand Name : Nexletol

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 17, 2021

                          Lead Product(s) : Bempedoic Acid,Ezetimibe,Atorvastatin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : ESPERION has entered into a definitive agreement with Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Serometrix developed the oral PCSK9 inhibitor program with its proprietary technology to discover drugs for difficult protein...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 13, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Preclinical

                          Recipient : Serometrix

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          10

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Both analyses demonstrated significant lowering of low-density lipoprotein cholesterol (LDL-C) by NEXLETOL® (bempedoic acid) Tablets by week 12 in specific subgroups, including people who cannot tolerate statins and females, compared to placebo.

                          Brand Name : Nexletol

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 13, 2020

                          Lead Product(s) : Bempedoic Acid

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank